Current Oncology
Clinical Utility of Drug-Eluting Beads Bronchial Arterial Chemoembolization in Advanced Refractory Non-Small Cell Lung Cancer
Par 李亚伟, Junqing Xi, Yuxi Liu et 2 autres.
Contenu en anglais
Résumé
Objective
This study mainly focused on evaluating the efficacy and safety of drug-eluting beads bronchial arterial chemoembolization (DEB-BACE) in treating advanced refractory non-small cell lung cancer (NSCLC) patients, with an exploratory investigation of whether combining DEB-BACE with anlotinib could bring additional benefits and identification of key prognostic factors.
Methods
A retrospective analysis was conducted on 104 eligible patients, including 64 who received DEB-BACE monotherapy and 40 who received DEB-BACE combined with anlotinib. Kaplan–Meier method, log-rank test, and Cox proportional hazard model were used for survival and prognostic analyses. Primary endpoints were progression-free survival (PFS) and overall survival (OS); secondary endpoints included objective response rate (ORR), disease control rate (DCR), and adverse events (AEs).